1
|
Fernandes JCR, Zamboni DS. Mechanisms regulating host cell death during Leishmania infection. mBio 2024; 15:e0198023. [PMID: 39392429 PMCID: PMC11559009 DOI: 10.1128/mbio.01980-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/12/2024] Open
Abstract
Parasites from the Leishmania genus are the causative agents of leishmaniasis and primarily reside within macrophages during mammalian infection. Their ability to establish intracellular infection provides a secure niche for proliferation while evading detection. However, successful multiplication within mammalian cells requires the orchestration of multiple mechanisms that control host cell viability. In contrast, innate immune cells, such as macrophages, can undergo different forms of cell death in response to pathogenic intracellular microbes. Thus, modulation of these different forms of host cell death is crucial for Leishmaniasis development. The regulation of host cell apoptosis, a form of programmed cell death, is crucial for sustaining parasites within viable host cells. Accordingly, several studies have demonstrated evasion of apoptosis induced by dermotropic and viscerotropic Leishmania species. Conversely, the prevention of pyroptosis, an inflammatory form of cell death, ensures the establishment of infection by silencing the release of mediators that could trigger massive proinflammatory responses. This manuscript explores how Leishmania regulates various host cell death pathways and overviews seminal studies on regulating host cell apoptosis by different Leishmania species.
Collapse
Affiliation(s)
- Juliane C. R. Fernandes
- Department of Cell Biology, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
| | - Dario S. Zamboni
- Department of Cell Biology, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
| |
Collapse
|
2
|
Baars I, Jaedtka M, Dewitz LA, Fu Y, Franz T, Mohr J, Gintschel P, Berlin H, Degen A, Freier S, Rygol S, Schraven B, Kahlfuß S, van Zandbergen G, Müller AJ. Leishmania major drives host phagocyte death and cell-to-cell transfer depending on intracellular pathogen proliferation rate. JCI Insight 2023; 8:e169020. [PMID: 37310793 PMCID: PMC10443809 DOI: 10.1172/jci.insight.169020] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Accepted: 06/05/2023] [Indexed: 06/15/2023] Open
Abstract
The virulence of intracellular pathogens relies largely on the ability to survive and replicate within phagocytes but also on release and transfer into new host cells. Such cell-to-cell transfer could represent a target for counteracting microbial pathogenesis. However, our understanding of the underlying cellular and molecular processes remains woefully insufficient. Using intravital 2-photon microscopy of caspase-3 activation in the Leishmania major-infected (L. major-infected) live skin, we showed increased apoptosis in cells infected by the parasite. Also, transfer of the parasite to new host cells occurred directly without a detectable extracellular state and was associated with concomitant uptake of cellular material from the original host cell. These in vivo findings were fully recapitulated in infections of isolated human phagocytes. Furthermore, we observed that high pathogen proliferation increased cell death in infected cells, and long-term residency within an infected host cell was only possible for slowly proliferating parasites. Our results therefore suggest that L. major drives its own dissemination to new phagocytes by inducing host cell death in a proliferation-dependent manner.
Collapse
Affiliation(s)
- Iris Baars
- Experimental Immunodynamics, Institute of Molecular and Clinical Immunology, Medical Faculty, and
- Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Faculty and Center for Health and Medical Prevention (CHaMP), Otto von Guericke University Magdeburg, Magdeburg, Germany
| | - Moritz Jaedtka
- Division of Immunology, Paul Ehrlich Institute, Langen, Germany
- Institute for Immunology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany
| | - Leon-Alexander Dewitz
- Experimental Immunodynamics, Institute of Molecular and Clinical Immunology, Medical Faculty, and
- Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Faculty and Center for Health and Medical Prevention (CHaMP), Otto von Guericke University Magdeburg, Magdeburg, Germany
| | - Yan Fu
- Experimental Immunodynamics, Institute of Molecular and Clinical Immunology, Medical Faculty, and
- Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Faculty and Center for Health and Medical Prevention (CHaMP), Otto von Guericke University Magdeburg, Magdeburg, Germany
| | - Tobias Franz
- Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Faculty and Center for Health and Medical Prevention (CHaMP), Otto von Guericke University Magdeburg, Magdeburg, Germany
- Institute of Molecular and Clinical Immunology, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany
| | - Juliane Mohr
- Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Faculty and Center for Health and Medical Prevention (CHaMP), Otto von Guericke University Magdeburg, Magdeburg, Germany
- Institute of Molecular and Clinical Immunology, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany
| | - Patricia Gintschel
- Experimental Immunodynamics, Institute of Molecular and Clinical Immunology, Medical Faculty, and
- Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Faculty and Center for Health and Medical Prevention (CHaMP), Otto von Guericke University Magdeburg, Magdeburg, Germany
| | - Hannes Berlin
- Experimental Immunodynamics, Institute of Molecular and Clinical Immunology, Medical Faculty, and
- Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Faculty and Center for Health and Medical Prevention (CHaMP), Otto von Guericke University Magdeburg, Magdeburg, Germany
| | - Angelina Degen
- Experimental Immunodynamics, Institute of Molecular and Clinical Immunology, Medical Faculty, and
- Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Faculty and Center for Health and Medical Prevention (CHaMP), Otto von Guericke University Magdeburg, Magdeburg, Germany
| | - Sandra Freier
- Experimental Immunodynamics, Institute of Molecular and Clinical Immunology, Medical Faculty, and
- Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Faculty and Center for Health and Medical Prevention (CHaMP), Otto von Guericke University Magdeburg, Magdeburg, Germany
| | - Stefan Rygol
- Experimental Immunodynamics, Institute of Molecular and Clinical Immunology, Medical Faculty, and
- Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Faculty and Center for Health and Medical Prevention (CHaMP), Otto von Guericke University Magdeburg, Magdeburg, Germany
| | - Burkhart Schraven
- Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Faculty and Center for Health and Medical Prevention (CHaMP), Otto von Guericke University Magdeburg, Magdeburg, Germany
- Institute of Molecular and Clinical Immunology, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany
| | - Sascha Kahlfuß
- Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Faculty and Center for Health and Medical Prevention (CHaMP), Otto von Guericke University Magdeburg, Magdeburg, Germany
- Institute of Molecular and Clinical Immunology, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany
| | - Ger van Zandbergen
- Division of Immunology, Paul Ehrlich Institute, Langen, Germany
- Institute for Immunology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany
- Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany
| | - Andreas J. Müller
- Experimental Immunodynamics, Institute of Molecular and Clinical Immunology, Medical Faculty, and
- Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Faculty and Center for Health and Medical Prevention (CHaMP), Otto von Guericke University Magdeburg, Magdeburg, Germany
- Helmholtz Centre for Infection Research, Braunschweig, Germany
| |
Collapse
|
5
|
Sun L, Chen Y, Luo H, Xu M, Meng G, Zhang W. Ca 2+/calmodulin-dependent protein kinase II regulation by inhibitor 1 of protein phosphatase 1 alleviates necroptosis in high glucose-induced cardiomyocytes injury. Biochem Pharmacol 2019; 163:194-205. [PMID: 30779910 DOI: 10.1016/j.bcp.2019.02.022] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Accepted: 02/15/2019] [Indexed: 12/20/2022]
Abstract
Ca2+/calmodulin-dependent protein kinase II (CaMKII) plays an important role in the cardiovascular system. However, the potential protective role of inhibitor 1 of protein phosphatase 1 (I1PP1), which is able to regulate CaMKII, in high glucose-induced cardiomyocytes injury remains unknown. In the present study, cardiomyocytes were transfected with I1PP1 adenovirus to inhibit protein phosphatase 1 (PP1) expression. After the cardiomyocytes were subjected to high glucose stimulation for 48 h, quantitative real-time PCR was used to detect CaMKIIδ alternative splicing. Lactate dehydrogenase (LDH) release and adenosine triphosphate (ATP) level were measured to assess cell damage and energy metabolism respectively. CaMKII activity was represented as phospholamban (PLB) phosphorylation, CaMKII phosphorylation (p-CaMKII) and oxidation (ox-CaMKII). Dihydroethidium (DHE), MitoSOX and JC-1 staining were used to assess oxidative stress and mitochondrial membrane potential. Necroptosis was evaluated by receptor interacting protein kinase 3 (RIPK3) expression, TUNEL and cleaved-caspase 3 levels. RIPK3, mixed lineage kinase domain like protein (MLKL) and dynamin-related protein 1 (DRP1) expressions were also detected. We found that high glucose disordered CaMKIIδ alternative splicing. I1PP1 over-expression suppressed PLB phosphorylation, ox-CaMKII, DRP1, RIPK3 and cleaved-caspase 3 proteins expression, decreased LDH release, attenuated necroptosis, increased ATP level, inhibited oxidative stress, and elevated mitochondrial membrane potential in high glucose-stimulated cardiomyocytes. However, there was no effect on phosphorylation of MLKL (p-MLKL), p-CaMKII, and receptor interacting protein kinase 1 (RIPK1) expression. Altogether, I1PP1 over-expression alleviated CaMKIIδ alternative splicing disorder, suppressed CaMKII oxidation, reduced reactive oxygen species (ROS) accumulation and inhibited necroptosis to attenuate high glucose-induced cardiomyocytes injury.
Collapse
Affiliation(s)
- Linlin Sun
- Department of Pharmacology, School of Pharmacy, Key Laboratory of Inflammation and Molecular Drug Target of Jiangsu Province, Nantong University, Nantong 226001, China
| | - Yun Chen
- Department of Pharmacology, School of Pharmacy, Key Laboratory of Inflammation and Molecular Drug Target of Jiangsu Province, Nantong University, Nantong 226001, China; School of Medicine, Nantong University, Nantong 226001, China
| | - Huiqin Luo
- Department of Pharmacology, School of Pharmacy, Key Laboratory of Inflammation and Molecular Drug Target of Jiangsu Province, Nantong University, Nantong 226001, China
| | - Mengting Xu
- Department of Pharmacology, School of Pharmacy, Key Laboratory of Inflammation and Molecular Drug Target of Jiangsu Province, Nantong University, Nantong 226001, China
| | - Guoliang Meng
- Department of Pharmacology, School of Pharmacy, Key Laboratory of Inflammation and Molecular Drug Target of Jiangsu Province, Nantong University, Nantong 226001, China; School of Medicine, Nantong University, Nantong 226001, China.
| | - Wei Zhang
- Department of Pharmacology, School of Pharmacy, Key Laboratory of Inflammation and Molecular Drug Target of Jiangsu Province, Nantong University, Nantong 226001, China.
| |
Collapse
|